|
Clinical IHC and immunoassay products for cancer detection |
||
|
| ||
|
|
||
|
Products for Oncology Diagnostics
GPC3 - Hepatocellular Carcinoma
p53 - Breast cancer
wnt2- Stomach cancer
Visit our IHC Products page for a complete list of reagents for the pathology lab |
Welcome to BioMosaics - BioMosaics is a biotechnology company engaged in the development, marketing and sale of diagnostic products for the early detection of cancer.
Revised Clinical Practice Guideline: Management of Hepatocellular Carcinoma >> "Biopsies of small lesions should be evaluated by expert pathologists. Tissue that is not clearly HCC should be stained with all the available markers including CD34, CK7, glypican 3, HSP-70, and glutamine synthetase to improve diagnostic accuracy." More info >>
Product Info (Catalog # B0025R) >> Glypican 3 antibody concentrate Product Info (Catalog # B0134R) >> pre-diluted, ready-to-use Glypican 3 antibody for IHC New Studies The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation Lai, JP et al., Hepatoloty, Jul 29; epub ahead of print, 2010. Link to PubMed >> Expression of MMP9 in predicting prognosis of hepatocellular carcinoma after liver transplantation Nart D et al., Liver Transp., 16 (5); p 621, 2010. Link to PubMed >> Product Info (Catalog # B2056M) >> |
|
|
Human p53-inducible gene 3 (PIG3) ELISA |
|
|
|
Copyright 2010 BioMosaics Inc. |
||
